 |
|
Is molecular adsorbent recirculating system effective for all the liver failure patients?
July 08, 2009Since its introduction in 1993, molecular adsorbent recirculating system (MARS) albumin dialysis has been a subject of research, with the hope of treating effectively patients with acute liver failure. The impact of MARS treatment on outcome as well as clinical and laboratory variables has been investigated widely in small non-randomized studies. However, larger studies with longer follow-up time are required to determine the true usefulness of MARS treatment in different liver failure etiologies.
An article to be published on June 28 2009 in the World Journal of Gastroenterology addressed this issue. The research led by Taru Kantola from Helsinki University Central Hospital, Finland discussed the prognostic factors for survival in patients with acute liver failure. The authors analysed the 1-year outcomes of 188 patients treated with MARS from 2001 to 2007, in an intensive care unit specializing in liver diseases.
They found that the etiology of liver failure was the most important predictor of survival. In acute liver failure (ALF) of toxic etiology (e.g., paracetamol), the grade of encephalopathy before MARS treatment was a significant prognostic factor. In ALF of unknown etiology, coagulation factor 5 and liver enzyme alanine aminotransferase levels were prognostic. According to the results, the MARS treatment of a cirrhotic patient with an acute-on-chronic liver failure is not meaningful in terms of prognosis if the patient is not eligible for transplantation.
World Journal of Gastroenterology
World Journal of Gastroenterology
Liver Failure Current Events and Liver Failure News RSSIs hepatic differentiation of embryonic stem cells induced by valproic acid and cytokines?
Embryonic stem (ES) cells, known for their capacity to proliferate indefinitely and differentiate into almost all types of cells including hepatocytes, have raised the hope of cellular replacement therapy for liver failure.
Governor recognizes stem cell research at Einstein
Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today.
Medication effective for acute liver failure in early stages of disease
The antidote for acute liver failure caused by acetaminophen poisoning also can treat acute liver failure due to most other causes if given before severe injury occurs, UT Southwestern Medical Center researchers and their colleagues at 21 other institutions have found.
First human gets new antibody aimed at hepatitis C virus
Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).
Hepatitis C infection: treatment options equally effective, likelihood of success known early on
Results of a long-awaited study of 3,070 American adults at Johns Hopkins and 118 other U.S. medical centers show that treatment with either of the two standard antiviral drug therapies is safe and offers the best way for people infected with hepatitis C to prevent liver scarring, organ failure and death.
June 25, 2009 A Trio of Signals Converge to Induce Liver and Pancreas Cell Development in the Embryo
Understanding the molecular signals that guide early cells in the embryo to develop into different organs provides insight into ways that tissues regenerate and how stem cells can be used for new therapies.
Liver disease 'shrunk' by blood-pressure drug
A blood-pressure medicine has been shown to reverse the effects of early-stage liver failure in some patients.
Novel antibody prevents infection by hepatitis C virus
Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the Hepatitis C virus (HCV).
2-day results predict ultimate response to therapy in chronic hepatitis C
A new study suggests that previously noted low rates of successful hepatitis C virus (HCV) therapy in African Americans are in large part due to very early differences in the antiviral activity induced by interferon.
Using math to understand hep. C: Patterns paint picture of who will respond to treatment
Genetic patterns are like the tea leaves in the bottom of a cup for predicting which patients are likely to respond to medical therapy for life-threatening viruses such as hepatitis C, Saint Louis University researchers have discovered.
More Liver Failure Current Events and Liver Failure News Articles
|
Gene therapy holds promise for treating liver failure, cirrhosis without need for transplants, studies find.(Brief Article): An article from: Transplant News by Transplant Communications, Inc. (Publisher) This digital document is an article from Transplant News, published by Transplant Communications, Inc. on March 13, 2000. The length of the article is 467 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Gene therapy holds promise for treating liver failure, cirrhosis without need for transplants, studies find.(Brief Article) Publication: Transplant News (Newsletter) Date: March 13, 2000 Publisher: Transplant Communications, Inc. Volume: 10 Issue: 5 Page: NA Article Type: Brief Article Distributed by Thomson... | |
 |
Resurrection Also With: Warner Bros. (Producer) |
 |
Failure of Liver Wrinkle Neck Mules (Primary Contributor) |
 |
A.H.P.B.A- 2005 Surgical Spring Week /DVD:28 Also With: American Hepato-Pancreato-Biliary Association (Host) A.H.P.B.A- 2005 Surgical Spring Week /DVD:28 SYMPOSIUM: Liver transplantation in Latin and South America . Cadaveric liver transplantation in Mexico - problems and solutions - Dr. Carlos Chan (Mexico) . Living donor liver transplantation for fulminant liver failure in Argentina - Dr. Oscar C. Andriani (Argentina) . Current status of liver transplant in Central and South America - Dr. Juan Hepp (Chile) |
 |
Standard Process Livaplex 90 Capsules (4-pack) by Standard Process |
|
Acute liver failure due to iron overdose in an adult.(Case Report): An article from: Southern Medical Journal by Sumanth R. Daram (Author), Paul H. Hayashi (Author) This digital document is an article from Southern Medical Journal, published by Southern Medical Association on February 1, 2005. The length of the article is 3559 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Acute liver failure due to iron overdose in an adult.(Case Report) Author: Sumanth R. Daram Publication: Southern Medical Journal (Refereed) Date: February 1, 2005 Publisher: Southern Medical Association Volume: 98 Issue: 2 Page: 241(4) Distributed by Thomson... | |
 |
Resource 2.0, Vanilla (formerly Novasource 2.0) 8 oz, 27/Case by Novartis Resource 2.0 is a calorically-dense, high nitrogen, complete liquid formula, specifically designed for the management of fluid restriction and elevated nutritional needs. It is designed with a reduced level of sodium which is often indicated for patients requiring fluid restriction. Resource 2.0 has a mild vanilla flavor and is appropriate for supplemental feeding including medication pass programs, as well as for total enteral feeding. Primary Indications: Medication pass programs, Wound prevention and treatment programs, Fluid restricted/volume sensitive patients, Congestive Heart Failure, Liver Disease with Ascites, Pulmonary Edema, Respiratory Disease, Shortened feeding schedules, Elevated Calorie and Protein Need |
|
Nefazodone labeling warns of Life-Threatening liver failure. (Drug Safety).(Brief Article): An article from: Clinical Psychiatry News by Damian McNamara (Author) This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on February 1, 2002. The length of the article is 699 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Nefazodone labeling warns of Life-Threatening liver failure. (Drug Safety).(Brief Article) Author: Damian McNamara Publication: Clinical Psychiatry News (Magazine/Journal) Date: February 1, 2002 Publisher: International Medical News Group Volume: 30 Issue: 2 Page: 9(1) Article Type: Brief Article Distributed by Thomson... | |
 |
Crisis of Conscience Also With: Warner Bros. (Producer) |
|
Infusion of hepatocytes can serve as bridge to liver transplant, rescue patients with acute liver failure.: An article from: Transplant News by Transplant Communications, Inc. (Publisher) This digital document is an article from Transplant News, published by Transplant Communications, Inc. on December 24, 1999. The length of the article is 385 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Infusion of hepatocytes can serve as bridge to liver transplant, rescue patients with acute liver failure. Publication: Transplant News (Newsletter) Date: December 24, 1999 Publisher: Transplant Communications, Inc. Volume: 9 Issue: 24 Page: NA Distributed by Thomson... |
| © 2009 BrightSurf.com |